Cue Biopharma (CUE) Share-based Compensation (2017 - 2025)

Cue Biopharma has disclosed Share-based Compensation across 9 years of filings, most recently posting $610000.0 for Q4 2025.

• Share-based Compensation for Q4 2025 came in at $610000.0, down 60.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.7 million (down 30.7% YoY), and the FY2025 annual result was $4.7 million, down 30.7% from the prior year.
• Share-based Compensation came in at $610000.0 for Q4 2025 at Cue Biopharma, down from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.3 million in Q3 2021 to a low of $610000.0 in Q4 2025.
• The 5-year median for Share-based Compensation is $2.1 million (2022), against an average of $2.0 million.
• Across the five-year window, Share-based Compensation soared 30.36% in 2021 and tumbled 60.95% in 2025, its largest moves.
• Cue Biopharma's Share-based Compensation stood at $3.0 million in 2021, then fell by 29.0% to $2.1 million in 2022, then fell by 1.89% to $2.1 million in 2023, then decreased by 24.61% to $1.6 million in 2024, then plunged by 60.95% to $610000.0 in 2025.
• The last three Share-based Compensation figures came in at $610000.0 (Q4 2025), $1.5 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.